Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioural, biochemical and histopathological alterations in mice brain

Kakkar, Vandita; Kaur, Indu Pal

doi:10.1016/j.fct.2011.08.006

Cited by 173 publications

(89 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 Previous studies have demonstrated the potential of curcumin-SLNs for treatment of Alzheimer's disease in male Lacca mice. 21 In this study, our aim was to investigate the therapeutic effect of curcumin-SLNs in the treatment of asthma. Curcumin loaded in SLNs was prepared using the solvent injection method.…”

mentioning

confidence: 99%

Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles

Wang

Zhu²,

Xie³

et al. 2012

IJN

166

View full text Add to dashboard Cite

Curcumin has shown considerable pharmacological activity, including anti-inflammatory, but its poor bioavailability and rapid metabolization have limited its application. The purpose of the present study was to formulate curcumin-solid lipid n anoparticles (curcumin-SLNs) to improve its therapeutic efficacy in an ovalbumin (OVA)-induced allergic rat model of asthma. A solvent injection method was used to prepare the curcumin-SLNs. Physiochemical properties of curcumin-SLNs were characterized, and release experiments were performed in vitro. The pharmacokinetics in tissue distribution was studied in mice, and the therapeutic effect of the formulation was evaluated in the model. The prepared formulation showed an average size of 190 nm with a zeta potential value of −20.7 mV and 75% drug entrapment efficiency. X-ray diffraction analysis revealed the amorphous nature of the encapsulated curcumin. The release profile of curcumin-SLNs was an initial burst followed by sustained release. The curcumin concentrations in plasma suspension were significantly higher than those obtained with curcumin alone. Following administration of the curcumin-SLNs, all the tissue concentrations of curcumin increased, especially in lung and liver. In the animal model of asthma, curcumin-SLNs effectively suppressed airway hyperresponsiveness and inflammatory cell infiltration and also significantly inhibited the expression of T-helper-2-type cytokines, such as interleukin-4 and interleukin-13, in bronchoalveolar lavage fluid compared to the asthma group and curcumin-treated group. These observations implied that curcumin-SLNs could be a promising candidate for asthma therapy.

show abstract

mentioning

confidence: 99%

Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles

Wang

Zhu²,

Xie³

et al. 2012

IJN

166

View full text Add to dashboard Cite

show abstract

“…A literature review showed curcumin solubility increases of 4-fold (22), 100-fold (12), 1000-fold (42), 4600-fold (31) and 3200-fold (32) when applying the solid dispersion concept. As a comparison, solubility increases of curcumin in cyclodextrin molecular inclusions were reported to be 31-fold (43), 190-to 200-fold (12) and 203-fold (39). Despite the best results in solubility improvement obtained by now were from ternary solid dispersions prepared by hot melt granulation (31) and spray drying (32), these forms had a very low curcumin load which difficult future applications in solid oral dosage forms (33).…”

Section: Discussionmentioning

confidence: 99%

“…Curcumin is an antioxidant compound and targets multiple chemotherapeutic and inflammatory pathways and has demonstrated safety and tolerability in humans; however, the clinical literature lacks conclusive evidence supporting its use as a therapeutic agent due to its low bioavailability (39).…”

Section: Discussionmentioning

confidence: 99%

Microparticles Containing Curcumin Solid Dispersion: Stability, Bioavailability and Anti-Inflammatory Activity

et al. 2015

View full text Add to dashboard Cite

Abstract. This work aimed at improving the solubility of curcumin by the preparation of spray-dried ternary solid dispersions containing Gelucire®50/13-Aerosil® and quantifying the resulting in vivo oral bioavailability and anti-inflammatory activity. The solid dispersion containing 40% of curcumin was characterised by calorimetry, infrared spectroscopy and X-ray powder diffraction. The solubility and dissolution rate of curcumin in aqueous HCl or phosphate buffer improved up to 3600-and 7.3-fold, respectively. Accelerated stability test demonstrated that the solid dispersion was stable for 9 months. The pharmacokinetic study showed a 5.5-fold increase in curcumin in rat blood plasma when compared to unprocessed curcumin. The solid dispersion also provided enhanced anti-inflammatory activity in rat paw oedema. Finally, the solid dispersion proposed here is a promising way to enhance curcumin bioavailability at an industrial pharmaceutical perspective, since its preparation applies the spray drying, which is an easy to scale up technique. The findings herein stimulate further in vivo evaluations and clinical tests as a cancer and Alzheimer chemoprevention agent.

show abstract

“…This confirmed that curcumin-loaded SLN will be a potential delivery system for the oral delivery of curcumin for AD treatment. 113 However, to further improve the bioavailability, curcumin-loaded MSLN was recently developed, and it showed improved delivery of the curcumin for AD treatment. Recently, resveratrol has gained more interest to treat AD due to its greater neuroprotective effect, and many studies confirmed that resveratrol treatment significantly improved the cognition and biochemical parameters.…”

Section: Anti-alzheimer's Effectmentioning

confidence: 99%

Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases

Ganesan

Ramalingam

Karthivashan

et al. 2018

IJN

127

View full text Add to dashboard Cite

Solid lipid nanoparticle (SLN) delivery systems have a wide applicability in the delivery of phyto-bioactive compounds to treat various chronic diseases, including diabetes, cancer, obesity and neurodegenerative diseases. The multiple benefits of SLN delivery include improved stability, smaller particle size, leaching prevention and enhanced lymphatic uptake of the bioactive compounds through oral delivery. However, the burst release makes the SLN delivery systems inadequate for the oral delivery of various phyto-bioactive compounds that can treat such chronic diseases. Recently, the surface-modified SLN (SMSLN) was observed to overcome this limitation for oral delivery of phyto-bioactive compounds, and there is growing evidence of an enhanced uptake of curcumin delivered orally via SMSLNs in the brain. This review focuses on different SLN and SMSLN systems that are useful for oral delivery of phyto-bioactive compounds to treat various chronic diseases.

show abstract

Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioural, biochemical and histopathological alterations in mice brain

Cited by 173 publications

References 74 publications

Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles

Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles

Microparticles Containing Curcumin Solid Dispersion: Stability, Bioavailability and Anti-Inflammatory Activity

Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases

Contact Info

Product

Resources

About